I kēia mau lā, ua hoʻokuʻu ʻo Novo Nordisk i kāna hōʻike kālā 2022. Hōʻike ka ʻikepili i ka huina kūʻai o Novo Nordisk ma 2022 e hōʻea i 176,954 biliona Denemaka krone (US $ 24,994 biliona, ka hoʻololi ʻana o ka hoʻololi ʻana i hoʻolaha ʻia ma ka hōʻike makahiki, ʻo ia hoʻi ma lalo), e piʻi ana i ka 26% makahiki ma ka makahiki, hiki i ka loaʻa kālā ke hōʻea i 74,809 biliona krone Denemaka. (US $10.566 biliona), piʻi 28% makahiki ma ka makahiki, a ʻo ka loaʻa kālā he 55.525 biliona Danish krone (US $ 7.843 biliona), piʻi 16% makahiki ma ka makahiki. He mea kupanaha ka hana.

No hea mai ka hana koʻikoʻi o Novo Nordisk? ʻO ka pane he GLP-1 analogue. I ka pipeline huahana o Novo Nordisk, hiki ke hoʻokaʻawale ʻia nā huahana i ʻehā mau ʻano: GLP-1 analogues, insulin a me nā analogues, coagulation factor a me nā hormones metabolic ʻē aʻe, me ke kūʻai aku ʻana o 83.371 biliona krone Danish ($ 11.176 biliona, ʻaʻole i hoʻokaʻawale i nā kola pohō kaumaha), 52.952 biliona Denemaka. krone ($7.479 billion), 11.706 billion Danish krone ($1.653 billion) a me 7.138 billion Danish krone ($1.008 billion), i kēlā me kēia. Ma waena o nā analogues GLP-1, ke emi nei ke kūʻai ʻana o Liraglutide hypoglycemic injection i kēlā me kēia makahiki, ʻoiai.SemaglutideHe mea hoihoi loa ia, me ka huina kuai o 10.882 biliona dala ma 2022.